logo
logo

Porton Biologics Announces Closing Series-A Financing To Drive Commercial Production Of Gene And Cell Therapy

Apr 19, 2021•about 4 years ago
Suzhou

Description

On April 16, 2021, Suzhou Porton Biologics Ltd. (hereinafter referred to as Porton Biologics), a subsidiary of Porton Pharma Solutions Ltd. (hereinafter referred to as Porton Pharma Solutions) (300363.SZ), which focuses on gene and cell therapy CDMO service, officially announced the closing of Series A funding round, which raised 400 million RMB. The participants of the financing include industry's top-tier investment institutions, SDIC and GL Ventures, HM Capital, Huashan Ruilian and Momentum Venture.

Company Information

Company

Porton Biologics

Location

Suzhou, Jiangsu, China

About

Founded in 2018, Suzhou Porton Biologics Ltd. (Portonbio) is located in Suzhou Industrial Park. As a subsidiary of the listed company Porton Pharma Solutions Ltd. (Stock Code: 300363), Porton Biologics has built an integrated CDMO platform covering plasmids, viral vectors and cell therapy for early studies, investigator-initiated clinical trial (IIT), investigational new drug (IND) filing, clinical trials  and commercial production, in order to advance clients' product into clinics and beyond.